Categories Analysis, Technology
Is Zoom Video Communications (ZM) a good investment after Q3 earnings?
The management's earnings and revenue guidance fell short of expectations, triggering a stock selloff
Zoom Video Communications (NASDAQ: ZM) expanded its customer base at an accelerated pace during the COVID crisis and soon became the preferred video conferencing platform for businesses and millions of people working/learning remotely. Though it continues to grow even after the market reopening there is a marked slowdown, raising concerns that the company is headed for a challenging year ahead.
ZM was one of the fastest-growing stocks when movement restrictions forced employees and students to adopt video conferencing services to stay connected and attend online classes. But the stock changed course once the initial boom waned and new players started hitting the market. More recently, interest rate hikes and high inflation sent stock markets into a tailspin, adding to Zoom’s troubles.
Weak Guidance
The weaker-than-expected full-year guidance issued by the company recently didn’t go well with investors despite Q3 earnings and revenue beating estimates, and the stock dropped sharply following the announcement this week. With that, Zoom’s shares have reversed most of their COVID-era gains and are currently trading at the lowest level in nearly three years.
Read management/analysts’ comments on quarterly reports
From the investment perspective, the valuation doesn’t look good even at the current lows, in relation to the company’s earnings and free cash flow performance. In what could be a concern for investors, sales have been under pressure lately, reflecting macroeconomic challenges and softness in enterprise spending on technology. While the downtrend is likely to continue, the company also faces the risk of growing competition from other players like Microsoft Teams and Cisco’s WebEx.
Buy ZM?
It is advisable to keep a tab on the company’s performance in future quarters before investing in it. Those who already own the stock might consider holding on until the picture becomes clearer. Meanwhile, the management is doing everything to stay on the growth path, with focus on innovation. It is betting high on the recent upgrade, incorporating new features like Zoom Mail and Calendar thereby making the platform an all-in-one service that enables users to create engaging virtual experiences.
GOOGL Earnings: All you need to know about Alphabet’s Q3 2022 earnings results
From Zoom’s Q3 2022 earnings call:
“Zoom is purpose-built to make all kinds of connections possible, effective, and meaningful. We have developed and launched more than 1,500 features and enhancements on the Zoom platform this year, advancing how people connect with each other, their organization, and their customers, ultimately, opening the doors wide for creativity and collaboration. Of course, even as we celebrate our innovations and customers, we still face the backdrop of a challenging macroeconomic environment.”
Q3 Outcome
Though revenues increased 5% to $1.1 billion in the third quarter it did not help the bottom line, rather adjusted earnings dropped 4% annually to $1.07 per share. In a sign that the weakness has extended into the current quarter, the management guided fourth-quarter earnings and revenue below the consensus estimates, triggering a stock selloff. It is worth noting that earnings exceeded estimates in every quarter since the company went public a few years ago.
Zoom’s stock ended Tuesday’s trading session sharply lower. Its value has more than halved since the beginning of 2022.
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on